Which peptides have the best evidence for your specific goal.
By Condition & Goal maps the questions people actually ask — which peptides have the best evidence for a torn tendon, for fat loss, for hair, for energy, for libido, for focus — to what the clinical record really supports. Each guide ranks the candidate peptides by evidence strength, not popularity, and is explicit about where the human data stops and the marketing begins.
A clinical, evidence-graded ranking of the peptides marketed for post-surgical recovery — thymosin alpha-1, thymosin β4/TB-500, GHK-Cu and BPC-157 — separating the one with human surgical RCT data from the rest, which are topical, negative, or preclinical only.
An evidence-graded review of the peptides marketed for osteoarthritis and joint degeneration. The honest 2026 verdict: the strongest human data belongs not to any joint-repair peptide but to GLP-1 metabolic drugs that relieve knee-OA pain by removing mechanical load.
Injuries & OrthopedicsA clinical, evidence-graded ranking of peptide drugs for osteoporosis — from the FDA-approved PTH-receptor anabolics with Grade A fracture-reduction RCTs to salmon calcitonin's regulatory demotion and the entirely unproven grey-market 'bone peptides.'
By Condition & GoalA clinical, evidence-first review of the peptides marketed to older adults for healthspan, muscle and cognition — ranked by what human data actually show, with the honest gap between the marketing and the science.
Energy, Cognition & MoodA clinical, evidence-graded ranking of the peptides marketed for neuroprotection — Cerebrolysin, Semax, ARA-290, SS-31/elamipretide and P021 — separating a modest, mixed human signal from elegant but preclinical-only mechanism.
Injuries & OrthopedicsA clinical, evidence-graded ranking of the peptides studied for nerve injury and neuropathy — ARA-290, Cerebrolysin, BPC-157 and Cortagen — separating genuine human RCT data from animal-only signal.
Injuries & OrthopedicsAn evidence-graded review of the peptides marketed for whiplash and neck soft-tissue injury. The honest 2026 verdict: there is no human evidence — no RCT, cohort, or registered trial — for any peptide in the cervical spine; the strongest case tops out at rat ligament and tendon models.
Injuries & OrthopedicsA clinical, evidence-graded review of the peptides marketed for hamstring pulls, calf and quad strains, and muscle tears — where the animal data are genuinely muscle-specific, and why no completed human trial yet proves any of them heals a strain.
Injuries & OrthopedicsAn evidence-graded review of the peptides marketed for muscle growth and lean mass — follistatin, CJC-1295, ipamorelin, MGF and IGF-1 LR3. The honest 2026 verdict: no peptide has Grade A human muscle-outcome data, and every one is prohibited in sport by WADA.
Energy, Cognition & MoodA clinical, evidence-first ranking of the peptides marketed for mitochondrial dysfunction — elamipretide (SS-31), MOTS-c, humanin and the SHLP family. Only one has any human bioenergetic data, and even that was acute and reversible.
Weight Loss & MetabolicAn evidence-graded review of the peptide drugs studied for metabolic syndrome — from the Grade A incretin drugs that reverse the whole cluster to the preclinical-only compounds sold online with no completed human trial.
Sexual & Hormonal HealthA clinical, evidence-first ranking of the peptides marketed for the menopause transition — separating the one FDA-approved molecule from the population-borrowed, preclinical, and mechanistically backwards claims.
Energy, Cognition & MoodA clinical, evidence-graded ranking of the peptides marketed for memory — Cerebrolysin, Semax, Noopept, Dihexa and P021 — separating the disputed human RCT signal from preclinical mechanism, a retracted-data scandal, and pure marketing.
By Condition & GoalAn evidence-first review of the peptides men buy for muscle, testosterone, libido and recovery — graded honestly by human data, with the FDA and WADA status that marketing leaves out.
Sexual & Hormonal HealthA clinical-editorial ranking of the peptides studied for low sexual desire in women — bremelanotide (PT-141/Vyleesi), kisspeptin and oxytocin — graded honestly. Only one is FDA-approved, and even that is a modest, as-needed tool.
Sexual & Hormonal HealthA clinical-editorial ranking of the peptides studied for male low libido — PT-141, kisspeptin and gonadorelin — graded honestly. The strongest evidence for male desire is correcting low testosterone, not a peptide.
Energy, Cognition & MoodA clinical, evidence-first review of the peptides marketed for long COVID (PASC) fatigue — thymosin alpha-1, elamipretide (SS-31), aviptadil and BPC-157. The blunt headline: no peptide has a positive long-COVID trial.
Weight Loss & MetabolicAn evidence-first ranking of the peptide drugs studied for fatty liver disease (NAFLD/MASLD) and steatohepatitis (MASH) — anchored in biopsy-confirmed human RCTs, not marketing.
Injuries & OrthopedicsA clinical, evidence-graded review of the peptides marketed for sprains, MCL tears and ACL injury — where the rat data are genuinely ligament-specific, and why no human trial yet proves any of them heals a torn ligament.
Immune, Gut & LongevityAn evidence-first ranking of the peptides studied for the intestinal barrier — teduglutide, larazotide acetate, BPC-157 and KPV — separating one Grade-A drug for a different condition from failed, abandoned or preclinical-only 'leaky gut' claims.
We rank by evidence strength, not by popularity or marketing. For each condition we look at the highest-quality human evidence available — randomized controlled trials first, then cohort and open-label studies — and grade each candidate A-D. A peptide with weak human data but strong rodent results is graded accordingly and ranked below better-evidenced options. Where no peptide has solid human evidence for a goal, we say so plainly rather than implying one works. Every ranking is informational, not a treatment recommendation.
No. These guides are educational and editorial. They explain what the evidence does and does not support for a given condition or goal, but they are not medical advice and they do not prescribe a protocol. Many peptides discussed are not FDA-approved and some are prohibited in sport. Any decision about your health should be made with a licensed clinician who knows your history, not from an article.
Popularity and evidence often diverge. Several heavily marketed peptides — including some best-sellers for injury recovery or fat loss — rest almost entirely on animal studies or anecdote, with no completed human trials. Our grading is conservative, so those compounds rank below peptides with genuine human data even when they are more famous. We always explain the gap between how a peptide is promoted and what has actually been proven in people.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.
